Home » Stocks » MREO

Mereo BioPharma Group PLC (MREO)

Stock Price: $3.10 USD 0.12 (4.03%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 335.56M
Revenue (ttm) n/a
Net Income (ttm) -224.15M
Shares Out 108.25M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $3.10
Previous Close $2.98
Change ($) 0.12
Change (%) 4.03%
Day's Open 3.08
Day's Range 2.94 - 3.14
Day's Volume 1,214,485
52-Week Range 1.19 - 4.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partners...

2 weeks ago - Benzinga

LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology an...

1 month ago - GlobeNewsWire

-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta ---- Further Strengthened Management Team ---- OncXerna Global Licensing Agreement for Navicixizumab ---- Stre...

1 month ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

2 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

3 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

3 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...

3 months ago - GlobeNewsWire

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CNSP, CYRN, NGD, RARE, XELA
4 months ago - InvestorPlace

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise

4 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

5 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

5 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

6 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

6 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...

6 months ago - GlobeNewsWire

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

6 months ago - GlobeNewsWire

Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call Transcript

7 months ago - Seeking Alpha

On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020

7 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on ...

7 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on ...

8 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on o...

8 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on o...

10 months ago - GlobeNewsWire

Operational progress, positioned for clinical milestones in oncology and rare diseases Operational progress, positioned for clinical milestones in oncology and rare diseases

11 months ago - GlobeNewsWire

Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio

11 months ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on r...

1 year ago - GlobeNewsWire

LONDON and REDWOOD CITY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Securities P...

1 year ago - GlobeNewsWire

Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching Sta...

1 year ago - GlobeNewsWire

Oncologie receives exclusive global license to develop and commercialize navicixizumab

1 year ago - GlobeNewsWire

Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for endocrine disorders in 2019. The focus this week is Mereo BioPharma.

1 year ago - Seeking Alpha

Mereo BioPharma has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

In 2019, the American Cancer Society estimates that about 22,530 women will receive a new diagnosis of ovarian cancer and that about 13,980 women will die from this disease in the United States alone.

1 year ago - 24/7 Wall Street

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Denise Scots-Knight
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
MREO
Full Company Profile

Financial Performance

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for MREO stock is "Strong Buy" and the 12-month stock price forecast is 664.20.

Price Target
$664.20
Analyst Consensus: Strong Buy